---
title: "Alkermes Q4 Earnings Summary & Key Takeaways"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276884094.md"
description: "Alkermes (NASDAQ:ALKS) reported its Q4 earnings on February 25, 2026, missing estimates by 23.68% with an EPS of $0.29 compared to the expected $0.38. Revenue decreased by $45.44 million year-over-year. In the previous quarter, Alkermes had exceeded EPS estimates by $0.12, leading to a 1.45% increase in share price the following day. Historical performance shows fluctuations in EPS and revenue across recent quarters."
datetime: "2026-02-25T12:06:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276884094.md)
  - [en](https://longbridge.com/en/news/276884094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276884094.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276884094.md) | [繁體中文](https://longbridge.com/zh-HK/news/276884094.md)


# Alkermes Q4 Earnings Summary & Key Takeaways

**Alkermes** (NASDAQ:ALKS) released its Q4 earnings on Wednesday, February 25, 2026 at 07:00 AM.

Here's what's important from the earnings announcement.

### Earnings

Alkermes missed estimated earnings by -23.68%, reporting an EPS of $0.29 versus an estimate of $0.38.

Revenue was down $45.44 million from the same period last year.

### Past Earnings Performance

The company beat on EPS by $0.12 in the last quarter, resulting in a 1.45% increase share price change the following day.

Here's a look at Alkermes's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

0.37

0.34

0.24

0.76

**EPS Actual**

0.49

0.52

0.13

1.04

**Revenue Estimate**

356.00M

340.26M

304.11M

379.42M

**Revenue Actual**

394.19M

390.66M

306.51M

429.99M

To track all earnings releases for Alkermes visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Alkermes plc (ALKS.US)](https://longbridge.com/en/quote/ALKS.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Alkem Laboratories Gets Board Nod to Boost Investment in New Factory](https://longbridge.com/en/news/281495465.md)
- [TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)](https://longbridge.com/en/news/281419637.md)
- [Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks](https://longbridge.com/en/news/281744101.md)
- [Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout](https://longbridge.com/en/news/281635912.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)